Fulcrum Therapeutics (FULC) Competitors $7.00 +0.01 (+0.14%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.00 0.00 (0.00%) As of 09/12/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FULC vs. EWTX, AUPH, CDTX, PAHC, ARDX, TWST, VERA, AVDL, COGT, and SNDXShould you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Edgewise Therapeutics (EWTX), Aurinia Pharmaceuticals (AUPH), Cidara Therapeutics (CDTX), Phibro Animal Health (PAHC), Ardelyx (ARDX), Twist Bioscience (TWST), Vera Therapeutics (VERA), Avadel Pharmaceuticals (AVDL), Cogent Biosciences (COGT), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry. Fulcrum Therapeutics vs. Its Competitors Edgewise Therapeutics Aurinia Pharmaceuticals Cidara Therapeutics Phibro Animal Health Ardelyx Twist Bioscience Vera Therapeutics Avadel Pharmaceuticals Cogent Biosciences Syndax Pharmaceuticals Edgewise Therapeutics (NASDAQ:EWTX) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends. Is EWTX or FULC more profitable? Edgewise Therapeutics' return on equity of -30.65% beat Fulcrum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Edgewise TherapeuticsN/A -30.65% -29.18% Fulcrum Therapeutics N/A -31.05%-28.96% Does the media prefer EWTX or FULC? In the previous week, Edgewise Therapeutics had 3 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 9 mentions for Edgewise Therapeutics and 6 mentions for Fulcrum Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.72 beat Fulcrum Therapeutics' score of 1.44 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Fulcrum Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, EWTX or FULC? Edgewise Therapeutics has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.82, indicating that its stock price is 182% more volatile than the S&P 500. Do analysts rate EWTX or FULC? Edgewise Therapeutics presently has a consensus price target of $40.55, suggesting a potential upside of 184.73%. Fulcrum Therapeutics has a consensus price target of $9.60, suggesting a potential upside of 37.14%. Given Edgewise Therapeutics' higher probable upside, research analysts plainly believe Edgewise Therapeutics is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.91Fulcrum Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in EWTX or FULC? 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 23.2% of Edgewise Therapeutics shares are owned by insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher earnings & valuation, EWTX or FULC? Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdgewise TherapeuticsN/AN/A-$133.81M-$1.55-9.19Fulcrum TherapeuticsN/AN/A-$9.73M-$1.22-5.74 SummaryFulcrum Therapeutics beats Edgewise Therapeutics on 7 of the 13 factors compared between the two stocks. Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FULC vs. The Competition Export to ExcelMetricFulcrum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$378.10M$3.19B$5.85B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-5.7421.4375.3425.98Price / SalesN/A429.44514.54181.13Price / CashN/A46.6837.5660.44Price / Book1.559.6112.156.29Net Income-$9.73M-$53.29M$3.29B$271.07M7 Day Performance-8.62%0.13%0.74%3.87%1 Month Performance2.19%5.61%4.82%4.88%1 Year Performance120.13%10.49%60.58%26.12% Fulcrum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FULCFulcrum Therapeutics2.6257 of 5 stars$7.00+0.1%$9.60+37.1%+103.5%$378.10MN/A-5.74100News CoveragePositive NewsShort Interest ↓EWTXEdgewise Therapeutics2.8068 of 5 stars$14.88-4.4%$40.55+172.5%-19.0%$1.64BN/A-9.6060Positive NewsAUPHAurinia Pharmaceuticals2.9211 of 5 stars$12.30-0.8%$12.00-2.4%+93.6%$1.63B$235.13M28.61300News CoveragePositive NewsCDTXCidara Therapeutics3.2753 of 5 stars$62.15-1.6%$64.14+3.2%+478.1%$1.60B$1.27M-5.5890Positive NewsPAHCPhibro Animal Health4.5324 of 5 stars$39.43-0.1%$28.40-28.0%+86.8%$1.60B$1.30B33.422,475Trending NewsInsider TradeAnalyst RevisionARDXArdelyx4.6295 of 5 stars$6.59+1.1%$11.70+77.5%+6.3%$1.57B$333.61M-28.6590News CoveragePositive NewsTWSTTwist Bioscience3.9713 of 5 stars$26.25+1.9%$49.40+88.2%-43.2%$1.55B$312.97M-18.10990News CoverageVERAVera Therapeutics3.044 of 5 stars$24.75+2.3%$63.00+154.5%-33.3%$1.54BN/A-6.9140Positive NewsAVDLAvadel Pharmaceuticals2.898 of 5 stars$15.38-2.4%$20.86+35.6%+10.4%$1.53B$221.08M-512.6770Positive NewsCOGTCogent Biosciences2.8709 of 5 stars$12.68-2.8%$20.00+57.7%+23.3%$1.49BN/A-7.1280Positive NewsSNDXSyndax Pharmaceuticals3.9147 of 5 stars$16.33-4.2%$38.89+138.1%-13.6%$1.47B$23.68M-4.20110Analyst Forecast Related Companies and Tools Related Companies EWTX Competitors AUPH Competitors CDTX Competitors PAHC Competitors ARDX Competitors TWST Competitors VERA Competitors AVDL Competitors COGT Competitors SNDX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FULC) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FULC Stock Alerts